Bliss GVS Pharma Limited has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, showcasing significant growth in its financial performance. The company’s consolidated revenue from operations for the quarter stood at ₹25,699.32 Lakhs, representing a 17.75% increase from the previous quarter’s ₹21,825.19 Lakhs and a 29.80% rise from ₹19,798.58 Lakhs in the same quarter last year. Consolidated net profit for the quarter reached ₹3,699.87 Lakhs, an increase of 49.31% over the ₹2,477.91 Lakhs reported in the preceding quarter and a 122.18% jump compared to ₹1,665.26 Lakhs in the corresponding quarter of the previous year. Along with these results, the Board recommended a final dividend of 100%, or ₹1 per equity share, for the financial year 2025-26.

Bliss GVS Pharma Limited is a fast-growing pharmaceutical company headquartered in Mumbai, India, with a strong global presence, particularly in Sub-Saharan Africa. The company specializes in the manufacturing and marketing of high-quality pharmaceutical formulations, including suppositories, pessaries, and other specialized dosage forms. With manufacturing facilities that adhere to international standards, Bliss GVS operates through several subsidiaries across India, Singapore, the UK, and Africa, including recent expansions such as Theralife Pharma Ltd in Kenya and Theralife Pharma RDC in the Democratic Republic of the Congo. The company is focused on providing affordable healthcare solutions globally and continues to strengthen its internal operations, as evidenced by the re-appointment of BDO India Services Private Limited as its internal auditor for the 2026-27 financial year.